Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer

 
• By Kevin Grogan

The Merkel cell carcinoma area is very niche but getting approval means that Merck and Pfizer can now prepare to compete with the likes of Opdivo and Keytruda in the European PD-1/PD-L1 space.

Running shoes
Out of the blocks: Bavencio is now approved in Europe • Source: Shutterstock

More from New Products

More from Scrip